All In Biotech

NDA 219108 · B Braun Medical

Rocuronium Bromide

Rocuronium Bromide · Intravenous

Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Oct 24, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

544

61 Phase 3, 36 recruiting

FAERS reports

5,786

5,018 serious, 441 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 17, 2026.

ROCURONIUM BROMIDE INJECTION is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. ROCURONIUM BROMIDE INJECTION is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Mechanism: Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 24, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
1 products under this application
  • ROCURONIUM BROMIDE · ROCURONIUM BROMIDE 50MG/5ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rocuronium" as an intervention, any sponsor and status, largest first.

All 544 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaphylactic shock693
  • drug ineffective690
  • anaphylactic reaction618
  • hypotension519
  • cardiac arrest355
  • tachycardia214
  • bronchospasm212
  • bradycardia197
  • rash182
  • drug interaction168
  • urticaria159
  • off label use157

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200551
200636
200755
2008107
2009177
2010196
2011267
2012270
2013116
2014150
2015138
2016263
2017209
2018272
2019375
2020314
2021303
2022415
2023487
2024459
2025542
2026566

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,129 on PubMed

Sponsor: B Braun Medical

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.